Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease

Drug Metabolism and Disposition

Volumn 37, Issue 10, 2009, Pages 2087-2094

  Fisher, Craig D ^a   Lickteig, Andrew J ^a   Augustine, Lisa M ^a   Ranger Moore, James ^a   Jackson, Jonathan P ^b   Ferguson, Stephen S ^c   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b CellzDirect Inc   (United States)

^c CellzDirect Life Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DICLOFENAC; DRUG METABOLIZING ENZYME; INTERLEUKIN 1BETA; MESSENGER RNA; TOLBUTAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ISOLATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FATTY LIVER; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER; MICROSOME; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEATOSIS; WESTERN BLOTTING;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; FATTY LIVER; HUMANS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RNA, MESSENGER;

EID: 70349292887     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027466     Document Type: Article

References (43)

1. Augustine LM, Fisher CD, Lickteig AJ, Aleksunes LM, Slitt AL, and Cherrington NJ (2008) Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats. J Biochem Mol Toxicol 22:93-100.
2. Bechtel YC, Haffen E, Lelouët H, Brientini MP, Paintaud G, Miguet JP, and Bechtel PR (2000) Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients. Int J Clin Pharmacol Ther 38:467-475. (Pubitemid 30765590)
3. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, and Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44-52. (Pubitemid 40911310)
4. Bellentani S, Bedogni G, Miglioli L, and Tiribelli C (2004) The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 16:1087-1093.
5. Chalasani N, Deeg MA, and Crabb DW (2004) Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99:1497-1502. (Pubitemid 39193189)
6. Chtioui H, Semela D, Ledermann M, Zimmermann A, and Dufour JF (2007) Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int 27:764-771. (Pubitemid 47062043)
7. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134. (Pubitemid 34106530)
8. Cuzick J (1985) A Wilcoxon-type test for trend. Stat Med 4:87-90.
9. Danielson PB (2002) The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 3:561-597. (Pubitemid 35331660)
10. Earley S, Pastuszyn A, and Walker BR (2003) Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am J Physiol Heart Circ Physiol 285:H127-H136. (Pubitemid 36736423)
11. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, and Branch RA (2006) Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 80:235-245. (Pubitemid 44313901)
12. George J, Liddle C, Murray M, Byth K, and Farrell GC (1995a) Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49:873-881.
13. George J, Murray M, Byth K, and Farrell GC (1995b) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21:120-128.
14. Gilmore WJ, Hartmann G, Piquette-Miller M, Marriott J, and Kirby GM (2003) Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression. Toxicology 184:211-226. (Pubitemid 36009302)
15. Guengerich FP (1994) Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett 70:133-138.
16. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70-83.
17. Guengerich FP and Turvy CG (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 256:1189-1194.
18. Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, and Huang KC (2007) Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 17:1457-1463.
19. Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, and Alaoui-Jamali MA (1996) Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 24:458-467. (Pubitemid 26274855)
20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321. (Pubitemid 40770284)
21. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259. (Pubitemid 24337433)
22. Krishna DR and Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144-160.
23. Lelouët H, Bechtel YC, Paintaud G, Brientini MP, Miguet JP, and Bechtel PR (2001) Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis. Int J Clin Pharmacol Ther 39:25-32. (Pubitemid 32048059)
24. Li L, Chen SH, Zhang Y, Yu CH, Li SD, and Li YM (2006a) Is the hypoxia-inducible factor-1 alpha mRNA expression activated by ethanol-induced injury, the mechanism underlying alcoholic liver disease? Hepatobiliary Pancreat Dis Int 5:560-563. (Pubitemid 44782096)
25. Li S, Hu ZH, and Miao XH (2006b) [Effects of chronic HBV infection on human hepatic cytochrome P450 3A4]. Zhonghua Yi Xue Za Zhi 86:2703-2706.
26. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, and Watkins PB (1992) The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51:229-238.
27. Lucas D, Berthou F, Dréano Y, Lozac'h P, Volant A, and Ménez JF (1993) Comparison of levels of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples. Alcohol Clin Exp Res 17:900-905.
28. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, and Busse R (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118:5489-5498. (Pubitemid 43079290)
29. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, and Gotoh O (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1-51. (Pubitemid 23064489)
30. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
31. Nichols KD and Kirby GM (2008) Microarray analysis of hepatic gene expression in pyrazolemediated hepatotoxicity: identification of potential stimuli of Cyp2a5 induction. Biochem Pharmacol 75:538-551.
32. Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, and Takagi I (2005) In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol 45:1221-1229. (Pubitemid 41513044)
33. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, and Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
34. Raunio H, Rautio A, Gullstén H, and Pelkonen O (2001) Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52:357-363. (Pubitemid 32939440)
35. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, and Muggeo M (2008) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51:444-450.
36. Tsunedomi R, Iizuka N, Hamamoto Y, Uchimura S, Miyamoto T, Tamesa T, Okada T, Takemoto N, Takashima M, Sakamoto K, et al. (2005) Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol 27:661-667.
37. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, Varela N, Contreras J, Lazarte R, Csendes A, et al. (2004) Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 106:261-268. (Pubitemid 38365832)
38. Villeneuve JP and Pichette V (2004) Cytochrome P450 and liver diseases. Curr Drug Metab 5:273-282.
39. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, and Liddle C (1998) Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27:128-133. (Pubitemid 28041545)
40. Wheeler CW and Guenthner TM (1990) Spectroscopic quantitation of cytochrome P-450 in human lung microsomes. J Biochem Toxicol 5:269-272.
41. Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, and Wu MC (2003) Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 9:359-363.
42. Zhou M, Maitra SR, and Wang P (2008) The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis. Int J Mol Med 21:423-428. (Pubitemid 351802636)
43. Zordoky BN and El-Kadi AO (2008) Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 9:122-128.